



Supplementary Figure



Supplementary Figure 1: tSNE representation of macrophages

A. tSNE (t-distributed Stochastic Neighbor Embedding) representation of pooled BCa patients (n=35) treated with isotype control. B. tSNE representation of pooled BCa patients treated with durvalumab. C. tSNE representation of pooled PCa patients (n=35) treated with isotype control. D. tSNE representation of pooled PCa patients treated with durvalumab.



Supplementary Figure 2: Link between level of periprostatic fat and ROS production by macrophages in PCa patients.

ROS production by macrophages (CD45⁺CD11b⁺HLADR⁺ROS⁺ cells) is significantly increased by durvalumab treatment in patient with low periprostatic fat (***p=00215**). ROS production by macrophages is unchanged after durvalumab treatment in patient with high periprostatic fat. Results are presented with individual patient changes (left) and overall group changes (right).

Supplementary Tables

Table S1: Antibodies used for cell staining

Antibody	Fluorochrome	Catalogue number
CD45	BUV395	563792
HLA-DR	PercpCy505	552764
CD11b	APC-cy7	301342
CD163	AF647	333620
B7H3 (CD276)	PeCy7	351008
CD206	BV605	740417
PD-L1 (CD274)	BV650	563740
PD-L2 (CD273)	BV421	563842
PD-1 (CD279)	Buv737	612791
Aqua Live Dead	BV510	L34957
CCR7 (CD197)	PE	552176
dihydrorhodamine123	FITC	D632
Phagocytosis Beads	Pecf594	L3030-1ML